{"id":32022,"date":"2025-04-18T14:57:48","date_gmt":"2025-04-18T06:57:48","guid":{"rendered":"https:\/\/flcube.com\/?p=32022"},"modified":"2025-04-18T14:57:49","modified_gmt":"2025-04-18T06:57:49","slug":"illumina-and-tempus-ai-collaborate-to-advance-next-generation-sequencing-in-clinical-practice","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32022","title":{"rendered":"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice"},"content":{"rendered":"\n

US major Illumina (NASDAQ: ILMN<\/a>) and Tempus AI, Inc. (NASDAQ: TEM<\/a>) are joining forces to enhance the clinical adoption of next-generation sequencing tests through innovative evidence generation. This collaboration will integrate Illumina’s cutting-edge AI technologies with Tempus\u2019s comprehensive multimodal data platform to train genomic algorithms and accelerate the integration of molecular testing into clinical practice.<\/p>\n\n\n\n

Partnership Details<\/strong>
The partnership focuses on utilizing Tempus\u2019s multimodal data to refine Illumina\u2019s AI-driven molecular analysis technologies. By combining these resources, the companies aim to generate novel insights that underscore the clinical value of sequencing. These insights will be used to develop evidence packages necessary for standardizing comprehensive genomic profiling and other molecular testing across major diseases.<\/p>\n\n\n\n

Clinical Impact<\/strong>
This initiative has the potential to significantly improve patient care by making molecular testing more accessible and actionable for clinicians. By standardizing the use of advanced genomic profiling, the collaboration aims to support more personalized and effective treatment decisions across various medical fields.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to…<\/p>\n","protected":false},"author":1,"featured_media":32024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,1639,1685,4014,4013],"class_list":["post-32022","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-illumina","tag-nasdaq-ilmn","tag-nasdaq-tem","tag-tempus-ai"],"yoast_head":"\nIllumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to enhance the clinical adoption of next-generation sequencing tests through innovative evidence generation. This collaboration will integrate Illumina's cutting-edge AI technologies with Tempus\u2019s comprehensive multimodal data platform to train genomic algorithms and accelerate the integration of molecular testing into clinical practice.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32022\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice\" \/>\n<meta property=\"og:description\" content=\"US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to enhance the clinical adoption of next-generation sequencing tests through innovative evidence generation. This collaboration will integrate Illumina's cutting-edge AI technologies with Tempus\u2019s comprehensive multimodal data platform to train genomic algorithms and accelerate the integration of molecular testing into clinical practice.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32022\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-18T06:57:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T06:57:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1807.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice\",\"datePublished\":\"2025-04-18T06:57:48+00:00\",\"dateModified\":\"2025-04-18T06:57:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022\"},\"wordCount\":177,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1807.webp\",\"keywords\":[\"AI\",\"Illumina\",\"NASDAQ: ILMN\",\"NASDAQ: TEM\",\"Tempus AI\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32022#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32022\",\"name\":\"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1807.webp\",\"datePublished\":\"2025-04-18T06:57:48+00:00\",\"dateModified\":\"2025-04-18T06:57:49+00:00\",\"description\":\"US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to enhance the clinical adoption of next-generation sequencing tests through innovative evidence generation. This collaboration will integrate Illumina's cutting-edge AI technologies with Tempus\u2019s comprehensive multimodal data platform to train genomic algorithms and accelerate the integration of molecular testing into clinical practice.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32022\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1807.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1807.webp\",\"width\":1080,\"height\":608,\"caption\":\"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32022#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice - Insight, China's Pharmaceutical Industry","description":"US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to enhance the clinical adoption of next-generation sequencing tests through innovative evidence generation. This collaboration will integrate Illumina's cutting-edge AI technologies with Tempus\u2019s comprehensive multimodal data platform to train genomic algorithms and accelerate the integration of molecular testing into clinical practice.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32022","og_locale":"en_US","og_type":"article","og_title":"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice","og_description":"US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to enhance the clinical adoption of next-generation sequencing tests through innovative evidence generation. This collaboration will integrate Illumina's cutting-edge AI technologies with Tempus\u2019s comprehensive multimodal data platform to train genomic algorithms and accelerate the integration of molecular testing into clinical practice.","og_url":"https:\/\/flcube.com\/?p=32022","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-18T06:57:48+00:00","article_modified_time":"2025-04-18T06:57:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1807.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32022#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32022"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice","datePublished":"2025-04-18T06:57:48+00:00","dateModified":"2025-04-18T06:57:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32022"},"wordCount":177,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32022#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1807.webp","keywords":["AI","Illumina","NASDAQ: ILMN","NASDAQ: TEM","Tempus AI"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32022#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32022","url":"https:\/\/flcube.com\/?p=32022","name":"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32022#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32022#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1807.webp","datePublished":"2025-04-18T06:57:48+00:00","dateModified":"2025-04-18T06:57:49+00:00","description":"US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to enhance the clinical adoption of next-generation sequencing tests through innovative evidence generation. This collaboration will integrate Illumina's cutting-edge AI technologies with Tempus\u2019s comprehensive multimodal data platform to train genomic algorithms and accelerate the integration of molecular testing into clinical practice.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32022#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32022"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32022#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1807.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1807.webp","width":1080,"height":608,"caption":"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32022#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1807.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32022"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32022\/revisions"}],"predecessor-version":[{"id":32025,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32022\/revisions\/32025"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32024"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}